What is Heru?
Heru operates at the intersection of medical technology and digital health, specializing in vision diagnostics and augmentation. The company's core value proposition lies in its ability to deliver clinical-grade diagnostic testing through portable, user-friendly interfaces. By replacing bulky, stationary equipment with sophisticated software, Heru is effectively democratizing access to high-quality eye care. This shift is particularly significant for healthcare providers looking to optimize clinical workflows and improve patient outcomes through data-driven insights. As a key innovator in the Miami technology corridor, Heru is actively challenging the status quo of traditional ophthalmology, providing practitioners with the tools necessary to perform comprehensive vision assessments with unprecedented efficiency.
How much funding has Heru raised?
Heru has raised a total of $32.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$30M
Angel/Seed (2020): $2.7M with participation from Maurice R. Ferre and Frederic H. Moll
Series A (2021): $30M led by Krillion Ventures, D1 Capital Partners, Frederic H. Moll, M.D., SoftBank Ventures Opportunity Fund, and Maurice R. Ferre, M.D.
Key Investors in Heru
Krillion Ventures
Krillion Ventures is a Miami-based venture capital fund that invests in early stage technology companies focused on healthcare, financial services, and real estate.
D1 Capital Partners
D1 Capital Partners is a global investment firm that manages capital for institutional investors and private clients, focusing on long-term value creation across diverse sectors.
Maurice R. Ferre
A prominent medical technology entrepreneur and investor with a deep focus on surgical robotics and diagnostic innovation.
What's next for Heru?
With the infusion of capital from its latest funding round, Heru is well-positioned to transition from a high-growth startup to an enterprise-level medical technology leader. The strategic focus will likely center on the commercialization of its diagnostic suite and the integration of its technology into broader clinical networks. By prioritizing research and development, the company aims to broaden its diagnostic capabilities, potentially addressing a wider array of ocular conditions. Furthermore, the backing from prominent venture capital firms suggests a robust roadmap for market penetration and long-term sustainability. As Heru continues to scale, the focus will remain on maintaining clinical rigor while navigating the complex regulatory landscape of the medical device industry, ultimately aiming to set a new standard for vision care delivery on a global scale.
See full Heru company page
